Polo-like Kinase 1 Licenses CENP-A Deposition at Centromeres

Kara L. McKinley¹ and Iain M. Cheeseman^{1,*}

¹Whitehead Institute and Department of Biology, MIT, Nine Cambridge Center, Cambridge, MA 02142, USA *Correspondence: icheese@wi.mit.edu

http://dx.doi.org/10.1016/j.cell.2014.06.016

SUMMARY

To ensure the stable transmission of the genome during vertebrate cell division, the mitotic spindle must attach to a single locus on each chromosome, termed the centromere. The fundamental requirement for faithful centromere inheritance is the controlled deposition of the centromere-specifying histone, CENP-A. However, the regulatory mechanisms that ensure the precise control of CENP-A deposition have proven elusive. Here, we identify polo-like kinase 1 (Plk1) as a centromere-localized regulator required to initiate CENP-A deposition in human cells. We demonstrate that faithful CENP-A deposition requires integrated signals from Plk1 and cyclin-dependent kinase (CDK), with Plk1 promoting the localization of the key CENP-A deposition factor, the Mis18 complex, and CDK inhibiting Mis18 complex assembly. By bypassing these regulated steps, we uncoupled CENP-A deposition from cell-cycle progression, resulting in mitotic defects. Thus, CENP-A deposition is controlled by a twostep regulatory paradigm comprised of Plk1 and CDK that is crucial for genomic integrity.

INTRODUCTION

During cell division, the genome must be segregated equally between the daughter cells. To accomplish this, the mitotic spindle must attach to each chromosome at a single locus, termed the centromere. Chromosomes lacking a functional centromere are unable to attach to the segregation apparatus, resulting in chromosome loss. In contrast, chromosomes with multiple centromeres can attach simultaneously to opposing spindle poles, resulting in chromosome missegregation and DNA damage. Indeed, chromosomes with multiple centromeres are frequently observed in cancers and can promote genomic instability and characteristics of tumorigenesis (Gisselsson et al., 2000; Gascoigne and Cheeseman, 2013).

In most eukaryotes, centromeres are specified epigenetically by the presence of the histone H3 variant, CENP-A (Black et al., 2010). Thus, centromere inheritance depends on the maintenance of CENP-A-containing nucleosomes at a single site on each chromosome. During DNA replication, existing CENP-A- containing nucleosomes are distributed to the replicated sister chromatids. Subsequently, CENP-A-containing nucleosomes must be replenished at centromeres. CENP-A deposition is restricted both spatially, to existing centromeres, and temporally, to G1 phase in human cells (Jansen et al., 2007). Current models suggest that this temporal restriction is crucial for faithful centromere inheritance and function (Gómez-Rodríguez and Jansen, 2013). However, the regulatory paradigms that control the propagation of this crucial epigenetic mark remain poorly understood.

The restriction of CENP-A deposition is accomplished at least in part through the regulated recruitment and function of its dedicated deposition machinery. In human cells, CENP-A incorporation is carried out by at least two sets of factors: the Mis18 complex, which assembles from Mis18 α , Mis18 β , and M18BP1/ KNL2 (Hayashi et al., 2004; Fujita et al., 2007; Maddox et al., 2007), and the CENP-A chaperone, HJURP (Dunleavy et al., 2009; Foltz et al., 2009). The full Mis18 complex localizes to centromeres beginning at anaphase onset (Hayashi et al., 2004; Fujita et al., 2007; Maddox et al., 2007; Figure 1A). HJURP recruitment and new CENP-A deposition then occur during G1 (Jansen et al., 2007; Dunleavy et al., 2009; Foltz et al., 2009; Figure 1A). Recent work demonstrated that cyclin-dependent kinase 1 and 2 (CDK1 and CDK2) negatively regulate CENP-A deposition to restrict this process to G1 (Silva et al., 2012). However, thus far, it has not been possible to uncouple CENP-A deposition from its temporal regulation without also disrupting cell cycle progression (Silva et al., 2012). This suggests that key mechanistic steps or regulatory paradigms for the control of CENP-A deposition remain to be defined.

We sought to determine the molecular basis for the regulation of CENP-A deposition. Our data establish a regulatory paradigm for CENP-A deposition that combines global regulation by CDK and a centromere-localized initiation signal provided by polo-like kinase 1 (Plk1). Defining the mechanisms by which Plk1 and CDK control CENP-A deposition allowed us to bypass the cell cycle regulation of CENP-A deposition, resulting in severe mitotic defects. Thus, the regulation of CENP-A deposition downstream of Plk1 and CDK is critical to protect the integrity of the genome.

RESULTS

Plk1 Displays Mis18 Complex-Dependent Localization to G1 Centromeres

To identify potential factors that regulate CENP-A deposition, we began by isolating GFP-Mis18 α by affinity purification from

~					
	GFP-Mis18 α	Mis18β-GFP	GFP-M18BP1	GFP-HJURP	New CENP-A
Anaphase	trates	Are the state of t	delt. Atom		
<u>6</u>			ing. Ng	an An	

В

GFP-Mis18a G1 IP

S	G2	M	G1	\rightarrow
1		1		
Release from hymidine block nto nocodazole	Harvest cells, w and ol	mitotic vashout oserve	Harvest	G1 sample

С

۸

Protein	% Sequenc	MW (kDa)	
	G1	AS	
Mis18α	18.9	27.5	25.9
Mis18β	48.5	48.5	24.7
M18BP1	15.3	33.3	129.1
Polo-like kinase 1	12.9	2.5	68.3





Figure 1. Plk1 Localizes to G1 Centromeres in a Mis18 Complex-Dependent Manner

(A) Images showing the localization of components of the CENP-A deposition pathway in anaphase and G1. Time-lapse images of single cells are shown for Mis18 α , Mis18 β , M18BP1, and HJURP. New CENP-A-SNAP was labeled with SNAP-Cell TMR-Star using a quench-pulse strategy (Jansen et al., 2007) in fixed cells. (B) Schematic describing the isolation of G1 samples of GFP-Mis18 α cells for analysis by mass spectrometry.

(C) Summary of mass spectrometry results following immunoprecipitation of GFP-Mis18a. Proteins shown are those identified in the GFP-Mis18a immunoprecipitation, but not in unrelated immunoprecipitations of other GFP-tagged proteins. AS, asynchronous sample generated from cells that failed to arrest in nocodazole.

(D) G1 localization of Plk1 tagged with YFP at the endogenous locus. Centromeres are marked with anti-centromere antibodies.

(E) Immunofluorescence images showing YFP-Plk1 localization in Mis18-complex-depleted cells (with γ adjustment). Centromeres are identified using anticentromere antibodies.

(F) Time-lapse images of YFP-Plk1 in Mis18 α -depleted cells. Numbers represent minutes after the metaphase image. Panels are not scaled equivalently but are scaled (with γ adjustment) to show the full range of data.

Scale bars, 5 $\mu m.$ See also Figure S1 and Tables S1, S2, S3, S4, and S5.

HeLa cells that were synchronized by mitotic shake off and then allowed to progress into G1 (Figure 1B). Mass spectrometry analysis identified the established components of the Mis18 complex—Mis18 α , Mis18 β , and M18BP1 (Figure 1C). In addition, we found that Plk1 copurified with the Mis18 complex (Figure 1C). The isolation of Plk1 with the Mis18 complex from G1 cells was unexpected, as Plk1 has been described predominantly as an M phase kinase (Barr et al., 2004). To assess the relevance of the association between the Mis18 complex and Plk1, we analyzed HeLa cells stably expressing yellow fluorescent protein (YFP)-Plk1. Prior work focused on the localization of Plk1 to centrosomes, mitotic kinetochores, the spindle midzone, and the midbody (Archambault and Glover, 2009). In addition, as reported by others (Arnaud et al., 1998; Kishi et al., 2009), we found that YFP-Plk1 localized to centromeres in G1, concurrent with Mis18 α localization (Figure S1A available online). We observed identical localization when we tagged the endogenous *PLK1* locus with YFP using CRISPR/Cas-mediated genome editing (Plk1-YFP) (Figure 1D). In contrast, the related polo-like kinases, Plk2 and Plk3, did not localize to G1 centromeres (Figure S1B). Depletion of Mis18 α or M18BP1 by RNAi abolished Plk1 localization to G1 centromeres (Figures 1E, 1F, S1C, and S1D). In contrast, Plk1 localization to the spindle midzone, midbody, and mitotic kinetochores was unaffected by Mis18 α or M18BP1 depletion (Figures 1E, 1F, and S1C; data not shown). These observations indicate that Plk1 localizes to G1 centromeres in a Mis18 complex-dependent manner.

Plk1 Activity Is Required for New CENP-A Deposition

The copurification of Plk1 with the Mis18 complex and the localization of Plk1 to G1 centromeres suggested that Plk1 might contribute to CENP-A deposition. To test this, we inhibited Plk1 kinase activity using the small molecule Bl2536 (Lénárt et al., 2007; Steegmaier et al., 2007) and assessed the incorporation of new CENP-A using a CENP-A-SNAP quench-pulse assay (Jansen et al., 2007; Figure 2A). We observed a dramatic defect in the deposition of new CENP-A following Bl2536 treatment (Figures 2A and S2A). We also observed a reduction in new CENP-A incorporation following treatment with the bulky ATP analog 3MB-PP1 in an RPE1 cell line expressing an analog-sensitive allele of Plk1 (Plk1^{as}) (Burkard et al., 2007; Figure S2B). These data indicate that Plk1 activity is required for CENP-A deposition.

In human cells, CENP-A deposition is restricted to the G1 phase of the cell cycle (Jansen et al., 2007). As Plk1 plays an established role in cell-cycle progression (Barr et al., 2004), we sought to test whether the observed defects in CENP-A deposition were due to global effects of Plk1 inhibition on cell state. However, the Bl2536-treated cells with a G1-like morphology that we analyzed for our experiments displayed cell-cycle markers consistent with an unperturbed G1 state, including increasing levels of nuclear Cdt1-RFP, minimal levels of geminin-GFP (Sakaue-Sawano et al., 2008), diffuse PCNA staining, and low cyclin B1 levels (Figures S2C and S2D). This suggests that Plk1 regulates CENP-A deposition independently of its previously reported effects on cell-cycle progression.

Recent work demonstrated that CENP-A deposition can be induced in S and G2 cells following the inhibition of CDK (Silva et al., 2012). As we also observed Plk1 localization to centromeres during S phase and G2 (Figure S2E), we tested whether CENP-A incorporation following CDK inhibition depended on Plk1. Treatment with Bl2536 severely disrupted CENP-A deposition in G2 cells following CDK inhibition (Figure 2B). These data indicate that Plk1-dependent regulation of new CENP-A deposition does not depend on residual CDK activity or regulatory circuits and events that are specific to mitotic exit, such as cytokinesis (Petronczki et al., 2007).

Previous work found that newly deposited CENP-A must be actively maintained by a process involving MgcRacGAP (Lagana et al., 2010), which is also a substrate of Plk1 (Wolfe et al., 2009). Therefore, we sought to test whether Plk1 was required to maintain new CENP-A at centromeres. To this end, we allowed cells with fluorescently labeled new CENP-A-SNAP to progress through G1 for 2.5 hr before the addition of BI2536. In this assay, we found that newly deposited CENP-A remained intact following BI2536 treatment (Figure 2C). In contrast, ongoing CENP-A deposition was halted following PIk1 inhibition (Figure 2C). This suggests that PIk1 is continuously required to direct CENP-A deposition but that it is not required to maintain newly incorporated CENP-A.

The Mis18 Complex and HJURP, but Not CENP-C, Require Plk1 Activity for Proper Localization to G1 Centromeres

We next sought to determine the mechanisms by which Plk1 promotes CENP-A incorporation. As a first step, we assessed the functional contributions of Plk1 to each step in the CENP-A deposition process. Previous work implicated the constitutive centromere protein CENP-C as a centromere-localized binding partner for the Mis18 complex (Moree et al., 2011; Dambacher et al., 2012). However, the functional contribution of CENP-C to Mis18 complex recruitment in mammalian cells has remained unclear (Dambacher et al., 2012). Therefore, we analyzed Mis18 complex localization following depletion of CENP-C by RNAi. As CENP-C depletion causes a mitotic arrest, we drove cells into G1 using an inhibitor of the checkpoint kinase Mps1. We found that depletion of CENP-C, but not the constitutive centromere protein CENP-T, strongly reduced Mis18 complex localization to G1 centromeres (Figure 3A), indicating that CENP-C is required for Mis18 complex recruitment. However, treatment with the Plk1 inhibitor Bl2536 did not affect CENP-C localization (Figure 3B), indicating that Plk1 inhibition does not result in the global destabilization of interphase centromeres.

We next tested the contribution of Plk1 to Mis18 complex localization. BI2536-treated cells displayed a substantial decrease in GFP-M18BP1 and mCherry- or GFP-Mis18a localization to G1 centromeres (Figures 3C and 3D), indicating that Plk1 activity is required for robust Mis18 complex localization. In addition to localizing to G1 centromeres, we found that GFP-M18BP1 localized to centromeres throughout mitosis (Figures S3A and S3B), consistent with previous reports for Xenopus laevis M18BP1 localization (Moree et al., 2011). Therefore, we also tested the effects of Plk1 inhibition on GFP-M18BP1 localization in both prometaphase and an anaphase-like state induced by CDK inhibition. In contrast to the defects observed in G1 cells (Figures 3C and 3F; t = 60 min after CDK inhibition), the prometaphase (Figure 3E) and anaphase-like (Figure 3F; t = 10 min after CDK inhibition) localization of M18BP1 was unaffected by Plk1 inhibition. Taken together, these data indicate that Plk1 is required to maintain the localization of the Mis18 complex at centromeres specifically during G1, the period when CENP-A deposition occurs.

Finally, we analyzed the effect of Plk1 inhibition on the centromere localization of the CENP-A chaperone, HJURP. Consistent with the defects in CENP-A deposition and Mis18 complex localization described above, Bl2536-treated cells exhibited striking defects in the centromere localization of GFP-HJURP (Figure 3G). These data indicate that Plk1 activity is required for multiple aspects of the CENP-A deposition process.

Mitotic shake-off Add BI2536/DMSO , Immunofluorescence Release from double thymidine block New CENP-A Centromeres Microtubules DMSO 878 B 100 ± 9.0 **BI2536** 6.7 ± 0.6 В С Label new CENP-A with Block existing CENP-A with non-fluorescent substrate Add Bl2536/DMSO Block existing CENP-A with non-fluorescent substrate fluorescent Immunofluorescence substrate substrate Release from double thymidine block Release from double thymidine block Mitotic shake-off Add BI2536/ DMSO Immunofluorescence Add CDKi thy 2.5 h 4 h **New CENP-A** Cyclin B Centromeres **CENP-A-SNAP fluorescence intensity** DMSO BI2536 250 CDKi + DMSO levels at 2.5 h) 200 150 100 ± 12 100 (% of | CDKi + Bl2536 50

Label new CENP-A with fluorescent substrate

Figure 2. Plk1 Activity Is Required for New CENP-A Deposition

 9.6 ± 1.9

Α

Block existing CENP-A with non-fluorescent substrate

(A) Top: schematic of the cell synchronization and CENP-A-SNAP labeling strategy to detect the deposition of newly synthesized CENP-A using a fluorescent quench-pulse strategy (Jansen et al., 2007). Mitotic cells were harvested and allowed to progress through G1 in the presence of BI2536 or DMSO for 2.5 hr before staining. Bottom: immunofluorescence images showing incorporation of new CENP-A-SNAP (labeled with SNAP-Cell Oregon Green) following treatment with BI2536 or DMSO. Centromeres are identified using anti-centromere antibodies. The microtubule morphology observed following BI2536 treatment is characteristic of failed cytokinesis due to Plk1 inhibition. Numbers represent CENP-A-SNAP centromeric fluorescence intensity as percent of control ± SEM; p < 0.001 (Student's t test); n = 20 G1 cell pairs.

2.5

4

Time after mitotic shakeoff (h)

(B) Top: schematic of the cell synchronization and CENP-A-SNAP labeling strategy used to test the Plk1 dependence of new CENP-A deposition in G2 phase following inhibition of CDK by flavopiridol (CDKi). Bottom: immunofluorescence images showing incorporation of new CENP-A-SNAP (labeled with SNAP-Cell TMR-Star) following treatment with BI2536 or DMSO and CDK inhibition. Centromeres are identified using anti-centromere antibodies. Numbers represent CENP-A-SNAP centromeric fluorescence intensity as percent of control ± SEM; p < 0.001 (Student's t test); n = 20 cyclin B^{high} cells.

(C) Top: schematic of the cell synchronization and CENP-A-SNAP labeling strategy used to test whether the maintenance of newly deposited CENP-A depends on Plk1. Bottom: quantification of centromeric fluorescence intensity of new CENP-A-SNAP (labeled with SNAP-Cell Oregon Green) as percent of levels at 2.5 hr ± SEM; n = 20 G1 cell pairs per condition per time point.

Scale bars, 5 μ m. See also Figure S2.

The Mis18 Complex Is a Key Target of Plk1 during CENP-A Deposition

To define the direct targets of Plk1, we performed in vitro kinase assays using recombinant components of the CENP-A deposition machinery. For these assays, we reconstituted the full Mis18 complex by coexpression of its subunits in bacteria (Figure S4A). Plk1 directly phosphorylated the Mis18 complex based on radioactive kinase assays (Figures 4A and S4B) and mass spectrometry analysis of in vitro phosphorylated samples (Figure S4C). In contrast, Plk1 did not efficiently phosphorylate HJURP or a C-terminal region of CENP-C containing the M18BP1-binding region (Moree et al., 2011; Dambacher et al., 2012) that we found to be necessary and sufficient for Mis18 complex recruitment (Figures 3A and 4A). These data suggest that the Mis18 complex is a major target of Plk1 in the CENP-A deposition pathway.

A subset of the phosphorylation sites in the Mis18 complex that we mapped in vitro has also been identified by mass spectrometry analysis of endogenous samples (Dephoure et al., 2008; Shiromizu et al., 2013; Figure S4C). To directly test whether the Mis18 complex is a substrate of Plk1 in vivo, we generated an antibody specific to phospho-T702 on M18BP1 (Figure S4D). This antibody detected centromeres by immunofluorescence in control cells, but not following M18BP1 RNAi (Figures 4B and S4E). Treatment with BI2536 abolished this signal (data not shown). However, it remained possible that the signal was eliminated because BI2536 treatment also causes Mis18 complex delocalization (Figure 3). To overcome this, we uncoupled Mis18 complex localization from Plk1 activity by generating an in-frame fusion between M18BP1 and the C-terminal domain of CENP-C described above (CENP-C-M18BP1) (Figure 4C). Localization of the CENP-C-M18BP1 fusion was unaffected by Plk1 inhibition (Figure 4D), consistent with the Plk1-independent localization of CENP-C (Figure 3B). Despite the continued localization of the CENP-C-M18BP1 fusion, the pT702 signal at centromeres was eliminated following BI2536 treatment (Figures 4E and 4F). Collectively, these data suggest that Plk1 directly phosphorylates the Mis18 complex in vitro and in cells.

Plk1 binds to many of its substrates via a phosphopeptidebinding module termed the polo-box domain (PBD) (Elia et al., 2003a). Therefore, we sought to determine if the Mis18 complex and the Plk1 PBD interact directly. Substrates are primed to interact with the PBD by kinases including CDK (Elia et al., 2003a) and Plk1 itself (known as self-priming; Burkard et al., 2007; Neef et al., 2007). We found that glutathione S-transferase (GST)-PBD bound robustly to the recombinant Mis18 complex by far-western analysis but only when the Mis18 complex had been previously phosphorylated with Plk1 (Figure 4G). Consistent with a Plk1 phosphorylation-dependent interaction between the Mis18 complex and the Plk1 PBD, we found that Plk1 localization to G1 centromeres required both a functional PBD and Plk1 kinase activity (Figure 4H). Therefore, Plk1 can phosphorylate and bind to the Mis18 complex directly via its PBD.

PIk1 Phosphorylation of the Mis18 Complex Promotes New CENP-A Deposition

To test the consequences of Mis18 complex phosphorylation by Plk1, we generated cell lines expressing RNAi-resistant versions of M18BP1, Mis18 α , or Mis18 β . Wild-type versions of these constructs were functional to carry out CENP-A deposition in the absence of the corresponding endogenous proteins (Figures 5A, and 5B, and S5A). We next generated mutants in which the mapped Plk1 phosphorylation sites were mutated to alanine to prevent their phosphorylation (Plk1-A mutants; see Table S2). In the presence of the endogenous proteins, these mutants displayed wild-type localization (data not shown), suggesting that these mutations do not substantially disrupt the structural integrity of these proteins.

To determine the importance of these phosphorylated residues for CENP-A deposition, we tested CENP-A incorporation in the mutant cell lines following depletion of the endogenous proteins by RNAi. Cells expressing mCherry-Mis18 α^{Plk1-A} , Mis18 β^{Plk1-A} -GFP, or coexpressing Mis18 α^{Plk1-A} and Mis18 β^{Plk1-A} did not display defects in new CENP-A deposition following depletion of their endogenous counterparts (Figure S5A). In contrast, cells expressing GFP-M18BP1^{Plk1-A} displayed severe defects in new CENP-A-SNAP incorporation following depletion of endogenous M18BP1 (Figures 5A and 5B). We attempted to mimic Plk1 phosphorylation by mutating the Plk1 phosphorylation sites to aspartate (GFP-M18BP1^{Plk1-D}). However, GFP-M18BP1^{Plk1-D} displayed similar defects in CENP-A deposition as GFP-M18BP1^{Plk1-A} (Figure S5B). We speculate that aspartate does not effectively mimic the phosphate group in this context and thus renders the mutant nonfunctional. These data indicate that Plk1 phosphorylation of M18BP1 is required for CENP-A deposition.

In the absence of endogenous M18BP1, we also observed a significant reduction in the levels of GFP-M18BP1^{Plk1-A} at centromeres (Figures 5A and 5C). To test whether the defect in M18BP1^{Plk1-A} localization was caused by a global decrease in the levels of kinetochore proteins due to defective CENP-A deposition, we tested the effect of directly depleting CENP-A by RNAi on GFP-M18BP1^{Plk1-A} localization (Figures S5C and S5D). CENP-A depletion had a minimal effect on GFP-M18BP1^{Plk1-A} levels (Figure S5D), consistent with previous reports demonstrating a limited reduction in CENP-C levels at a similar time point following induction of a conditional CENP-A knockout (Fachinetti et al., 2013). This suggests that the observed reduction in M18BP1^{Plk1-A} localization is due to a defect intrinsic to the mutant. Collectively, these data demonstrate that direct phosphorylation of the Mis18 complex by Plk1 promotes M18BP1 localization and new CENP-A deposition.

The identified Plk1 phosphorylation sites in M18BP1 are present throughout the protein (Figure 5D). We found that an N-terminal (NT) region (amino acids 1–490; M18BP1-NT) was sufficient for M18BP1 centromere localization and Mis18 α recruitment (Figures S5E and S5F) and was functional to restore CENP-A deposition to M18BP1-depleted cells (Figures 5E and 5F). Therefore, we tested the requirements for the Plk1 phosphorylation sites that we identified in this region (GFP-M18BP1^{Plk1-A}-NT; Figure 5D). GFP-M18BP1-NT showed robust centromere localization in the presence and absence of endogenous M18BP1 (Figures 5E and 5G). In contrast, GFP-M18BP1^{Plk1-A}-NT localized weakly to centromeres in the presence of the endogenous protein (Figure S5G), and this



Figure 3. Plk1 Is Required for the Localization of the Mis18 Complex and HJURP to G1 Centromeres

(A) Live-cell images of GFP-Mis18α cells following 48 hr treatment with siRNAs against the indicated targets. Penetrant RNAi was confirmed by observation of a disorganized metaphase plate before cells were driven into G1 using an Mps1 inhibitor (Mps1i; AZ3146) for 1 hr. The Mis18α recruitment defect observed in CENP-C RNAi can be rescued by expression of the RNAi-resistant CENP-C C terminus (CT: amino acids 510–934). Right: depletion of the constitutive centromere protein CENP-T does not affect Mis18α localization.

(B) Immunofluorescence images showing localization of CENP-C following treatment with DMSO or Bl2536. Numbers represent centromeric fluorescence intensity as percent of control \pm SEM; n = 20 G1 cell pairs; p > 0.05 (Student's t test).

(C) Immunofluorescence images showing GFP-Mis18 α localization following treatment with BI2536 or DMSO. Numbers represent centromeric fluorescence intensity as percent of control \pm SEM; n = 20 G1 cell pairs; p < 0.001 (Student's t test).

localization was further reduced upon depletion of endogenous M18BP1 (Figures 5E and 5G). In addition, CENP-A deposition was severely defective in cells expressing GFP-M18BP1^{Plk1-A}-NT following M18BP1 RNAi (Figures 5E and 5F). These data indicate that Plk1 phosphorylation of the N terminus of M18BP1 is critical for M18BP1 localization and function.

The phenotypes observed in the M18BP1^{Plk1-A} mutant suggest that Plk1 phosphorylation of M18BP1 promotes its localization and new CENP-A incorporation. To distinguish whether the primary function of Plk1 during CENP-A deposition is to regulate M18BP1 localization, we bypassed the regulated M18BP1 localization using the CENP-C-M18BP1 fusion. As described above, in the absence of the CENP-C fusion partner, M18BP1^{Plk1-A} displayed severely defective CENP-A deposition following M18BP1 depletion (Figures 5A and 5B). In contrast, CENP-C-M18BP1^{Plk1-A} partially restored CENP-A deposition to M18BP1-depleted cells (Figure S5H), although to a lesser extent than wild-type CENP-C-M18BP1. This suggests that Plk1 phosphorylation of M18BP1 primarily affects CENP-A deposition by modulating M18BP1 localization.

Cyclin-Dependent Kinase Regulates Mis18 Complex Assembly

The combination of these data demonstrates that Plk1 acts as a key regulator for CENP-A deposition and functions at least in part through modulating M18BP1 localization. Previous work demonstrated that CDK1/CDK2 activity inhibits CENP-A deposition (Silva et al., 2012). We therefore sought to define the mechanisms by which these two kinases coordinately regulate the CENP-A deposition process. CDK has been proposed to act by restricting M18BP1 localization to anaphase and G1 (Silva et al., 2012). However, when we mutated the full complement of serine and threonine residues corresponding to CDK consensus phosphorylation sites to alanine (GFP-M18BP1^{CDK-A}; Table S2), we found that this mutant displayed similar temporal localization to wildtype GFP-M18BP1, localizing to centromeres from mitotic entry through G1 (data not shown). In contrast, Mis18 α and Mis18 β did not localize until anaphase onset (Figures S3A and 1A), suggesting that assembly of the Mis18 complex is cell cycle regulated.

To test whether CDK controls the recruitment of Mis18 α and Mis18 β , we next used the CENP-C-M18BP1 fusion, which localizes to centromeres constitutively (Figure S6A). Despite the constitutive localization of CENP-C-M18BP1, Mis18 α localiza-

tion remained restricted to anaphase/G1 in cells expressing this fusion (Figure S6A). In contrast, expression of a fusion between the CENP-C C-terminal domain and M18BP1^{CDK-A} (CENP-C-M18BP1^{CDK-A}) resulted in premature GFP-Mis18 α recruitment (Figure 6A). These data indicate that the CDK-dependent inhibition of CENP-A deposition occurs at least in part through preventing assembly of the Mis18 complex at centromeres.

We next sought to determine whether Plk1 and CDK regulate separate aspects of the CENP-A deposition pathway. Premature mitotic recruitment of Mis18 α in cells expressing CENP-C-M18BP1^{CDK-A} was not affected by Bl2536 treatment or mutation of the Plk1 phosphorylation sites in M18BP1 alongside the CDK sites (CENP-C-M18BP1^{CDK-A-Plk1-A}; Table S2; Figures S6B and S6C). Thus, Plk1 is not required for the assembly of the Mis18 complex. Overall, our data suggest that Plk1 and CDK control distinct steps in the CENP-A deposition process, with CDK regulating Mis18 complex assembly and Plk1 regulating M18BP1 localization.

The Cell-Cycle Restriction of CENP-A Deposition Is Crucial for Genomic Integrity

The results above define key regulatory steps for the control of the CENP-A deposition process downstream of Plk1 and CDK. To determine if additional regulatory steps are required to promote CENP-A deposition, we sought to bypass these steps and uncouple CENP-A deposition from its normal cell cycle restriction. Although cells expressing the CENP-C-M18BP1^{CDK-A} fusion recruit Mis18 α to mitotic centromeres, we did not observe new CENP-A deposition during mitosis at the expression levels tested (Figures 6B and 6C). As our work suggested that Plk1 and CDK both regulate steps upstream of Mis18 α recruitment, we directly targeted Mis18 α to centromeres. Strikingly, in cells expressing a fusion between the CENP-C C-terminal domain and Mis18 α (CENP-C-Mis18 α), we observed newly deposited CENP-A-SNAP at centromeres in S, G2, and M phase cells (Figures 6B–6D and S6D).

To determine whether CENP-A deposition is actively occurring throughout the cell cycle in cells expressing the CENP-C-Mis18 α fusion, we analyzed the localization of the CENP-A chaperone, HJURP. In wild-type cells, HJURP recruitment is restricted to G1 phase, concurrent with CENP-A deposition (Figures 1A and 6E). In contrast, we observed HJURP localization to centromeres in S, G2, and M phase cells expressing the CENP-C-Mis18 α

⁽D) Time-lapse images of live cells coexpressing GFP-M18BP1 and mCherry-Mis18 α following treatment with BI2536 or DMSO. BI2536 was added in early anaphase. Numbers indicate minutes after BI2536 addition.

⁽E) Quantification of centromeric GFP-M18BP1 levels in live prometaphase-like cells following treatment with Bl2536. Cells were treated with the Eg5 inhibitor STLC for 4 hr to induce a mitotic arrest before addition of Bl2536 or DMSO for 1 hr. Numbers are presented as fold enrichment over initial centromeric fluorescence \pm SEM; n = 10 cells. NS, not significant; p > 0.05 (Student's t test).

⁽F) Quantification of centromeric GFP-M18BP1 levels in live cells following treatment with BI2536. To avoid confounding effects due to delays in uptake and function of the drug, cells were pretreated with BI2536 for 1 hr. As a control, cells were treated with STLC, which, like BI2536, induces a mitotic arrest with monopolar spindle. To bypass the arrest, mitotic exit was induced with the CDK inhibitor flavopiridol for both BI2536- and STLC-treated cells. Times after CDK inhibition were chosen to correspond to anaphase (10 min) and G1 (60 min). Numbers are presented as fold increase over centromeric fluorescence at t = 0 \pm SEM; n = 10 cells. ***p < 0.001 (Student's t test).

⁽G) Immunofluorescence images showing localization of GFP-HJURP following treatment with BI2536 or DMSO. Centromeres are identified using anticentromere antibodies. The images are not scaled equivalently but are scaled to show the full range of the data. Numbers represent centromeric fluorescent intensity as percent of control \pm SEM; n = 20 G1 cell pairs; p < 0.001 (Student's t test). Scale bars, 5 μ m. See also Figure S3.







(legend on next page)

fusion (Figure 6E). This suggests that CENP-C-Mis18 α -expressing cells incorporate new CENP-A throughout the cell cycle. To test whether CENP-C-Mis18 α expression bypasses the requirement for Plk1, we treated cells with Bl2536 immediately following the quenching of existing CENP-A-SNAP with nonfluorescent substrate and allowed cells to progress through S phase in the presence of the inhibitor. In CENP-C-Mis18 α -expressing cells, CENP-A deposition continued following Bl2536 treatment (Figure 6F), indicating that Plk1 acts upstream of Mis18 α localization to control CENP-A deposition.

To test the consequences of uncoupling CENP-A incorporation from its cell cycle regulation, we analyzed the behavior of mitotic cells expressing the CENP-C-Mis18 α fusion. Intriguingly, cells expressing the CENP-C-Mis18 α fusion exhibited severe mitotic defects including dramatically misaligned chromosomes and multipolar spindles (Figures 6G and 6H). These phenotypes are consistent with defective centromere and kinetochore function. In contrast, cells expressing the CENP-C C-terminal fragment alone displayed infrequent mitotic defects (Figure 6H). These data suggest that the precise control of CENP-A deposition downstream of CDK and Plk1 is critical for proper chromosome segregation and genomic integrity.

DISCUSSION

A key goal of the ongoing research in centromere biology has been to define the epigenetic mechanisms that direct the sequence-independent propagation of centromeres. However, the regulatory mechanisms that ensure proper centromere inheritance have remained elusive. Recent work demonstrated that CDK contributes to the cell-cycle restriction of centromere inheritance by globally inhibiting CENP-A deposition (Silva et al., 2012). Here, we defined the requirement for a positive, centromere-localized regulatory signal provided by Plk1 to initiate CENP-A deposition (Figure 7). This dual control of CENP-A deposition-combining global CDK regulation with a site-specific licensing kinase-is analogous to the paradigms that ensure the fidelity of other key cell cycle events. For example, although cellular changes in CDK activity are required to restrict DNA replication and centriole duplication to specific windows of the cell cycle, the initiation of these processes requires the licensing kinase Dbf4-dependent kinase to act at

To precisely define the roles for Plk1 and CDK in CENP-A deposition, we dissected the regulation of each step in the CENP-A deposition process. In particular, we analyzed three key points of regulation: (1) M18BP1 localization to centromeres, (2) Mis18 complex assembly, and (3) new CENP-A deposition by the CENP-A chaperone HJURP. We found that Plk1 is required for CENP-A deposition downstream of CENP-C localization but upstream of Mis18a recruitment. Further, we defined the Mis18 complex as a direct substrate of Plk1 and demonstrated that Plk1 phosphorylation of M18BP1 promotes its localization and CENP-A deposition. These data indicate that M18BP1 is a key functional target of Plk1. We cannot exclude the possibility that Plk1 phosphorylation of other components of the CENP-A deposition pathway contributes to CENP-A incorporation. However, as the CENP-C-Mis18a fusion bypasses the requirement for Plk1 to promote CENP-A deposition, Plk1 phosphorylation of HJURP or MgcRacGAP, which function downstream of Mis18a localization (Lagana et al., 2010; Barnhart et al., 2011), is unlikely to play a critical role. In addition, although our data suggest that Plk1 phosphorylation controls CENP-A deposition primarily by regulating M18BP1 localization, artificial targeting of M18BP1 to centromeres as a CENP-C fusion does not fully bypass the requirement for Plk1 activity. In particular, we find that the CENP-C-M18BP1^{Plk1-A} fusion does not fully restore CENP-A deposition in the absence of endogenous M18BP1. Thus, the phosphorylation sites in M18BP1 may regulate aspects of M18BP1 function in addition to controlling its localization.

In addition to identifying Plk1 as a regulator of M18BP1 localization, we also demonstrated that the assembly of the Mis18 complex is regulated by CDK. However, our data indicate that Plk1 and CDK act independently to control distinct steps during this process. For example, the regulation of M18BP1 localization by Plk1 does not require CDK activity, and regulation of Mis18 complex assembly by CDK does not require Plk1 phosphorylation. Thus, CENP-A deposition is accomplished by a two-step regulatory mechanism integrating critical signals from Plk1 and CDK. Together, these regulators provide the temporal and spatial cues to precisely control CENP-A deposition (Figure 7).

Figure 4. Plk1 Binds to and Phosphorylates the Mis18 Complex

Scale bars, 5 $\mu m.$ See also Figure S4.

⁽A) Autoradiogram showing Plk1 phosphorylation of recombinant proteins in the CENP-A deposition pathway in the presence of ³²P-ATP. The approximate migration of each protein is indicated on the right based on GelCode Blue staining (see Figure S4B).

⁽B) Immunofluorescence images of G1 cells expressing GFP-Mis18 α , costained with α -M18BP1 pT702. Centromeres are marked with α -CENP-A antibodies. (C) Schematic of the CENP-C-M18BP1 fusion used to bypass regulated M18BP1 localization. Numbers represent amino acid positions within CENP-C.

⁽D) Quantification of mCherry-CENP-C-M18BP1 levels following treatment with BI2536 or DMSO as percent of DMSO levels. Both DMSO and BI2536-treated populations were depleted for endogenous M18BP1. The error bars represent SEM; n = 20 G1 cell pairs.

⁽E) Immunofluorescence images showing CENP-C-M18BP1-expressing cells stained for α -M1B81P pT702 following treatment with BI2536. Centromeres are identified with α -CENP-A antibody.

⁽F) Quantification of pT702 centromeric fluorescence in CENP-C-M18BP1-expressing cells following treatment with BI25356 (quantification of Figure 4E). The error bars represent SEM; n = 20 G1 cell pairs; *** p < 0.001 (Student's t test).

⁽G) Far-western analysis of recombinant GST-PBD binding to the recombinant Mis18 complex in the presence or absence of Plk1.

⁽H) Left: schematic of modified GFP-Plk1 constructs. Right: immunofluorescence images showing localization of modified GFP-Plk1 constructs: PBD alone (PBD truncation + nuclear localization signal), FL PBD dead (full-length protein with mutations rendering the polo-box unable to bind to its substrates; Elia et al., 2003b), FL + Bl2536 (full-length protein after treatment with the Plk1 inhibitor Bl2536). Images are scaled with γ adjustment.



Figure 5. Plk1 Phosphorylation of the Mis18 Complex Is Required for CENP-A Deposition

(A) Immunofluorescence images showing new CENP-A-SNAP deposition in cells expressing GFP fusions of either M18BP1^{WT} or M18BP1^{Pik1-A} following treatment with the indicated siRNAs. New CENP-A-SNAP is labeled using SNAP-Cell TMR-Star.

(B) Quantification of centromeric fluorescence intensity of new CENP-A-SNAP following replacement of endogenous M18BP1 with RNAi-resistant GFP-M18BP1^{WT} or GFP-M18BP1^{Plk1-A}. Numbers are presented as a percentage of the intensity in M18BP1^{WT} cells + control RNAi. The error bars represent SEM; n = 20 G1 cell pairs. ***p < 0.001 (Student's t test). Wild-type and mutant cell lines were generated from the same parental CENP-A-SNAP cell line (see Table S1) and after generation continue to have equivalent levels of total CENP-A-SNAP protein (data not shown). WT, wild-type.

(C) Quantification of centromeric GFP-M18BP1^{WT} or GFP-M18BP1^{Plk1-A} fluorescence intensity in cells in which M18BP1 has been depleted. The error bars represent SEM; n = 20 G1 cell pairs. ***p < 0.001 (Student's t test).

Underlying the efforts to define the mechanisms that regulate CENP-A deposition is the assumption that the observed cell cycle restriction of this process is functionally important for the propagation or function of this epigenetic mark. By defining the key molecular events required for CENP-A deposition and their regulation, we developed a strategy to bypass the cell cycle regulation of this process. We found that bypassing Plk1 and CDK regulation by expression of a CENP-C-Mis18a fusion induced CENP-A deposition throughout the cell cycle, resulting in severe mitotic defects. This indicates that the precise regulation of CENP-A deposition by Plk1 and CDK is crucial for proper chromosome segregation. These data raise exciting new questions regarding the molecular consequences of uncoupling CENP-A deposition from cell cycle progression. For example, CENP-A deposition during S phase alongside canonical H3 may disrupt centromere integrity or mitotic CENP-A deposition could destabilize chromosome condensation at centromeres. Ongoing CENP-A deposition during mitosis may also affect kinetochore assembly, either by preventing the recruitment of key kinetochore components or by generating additional sites for kinetochore formation and thereby disrupting the higher-order organization of the kinetochore. Together, our data define key roles for Plk1 and CDK in regulating CENP-A deposition and establish the vital importance of this regulation for ensuring genomic integrity.

EXPERIMENTAL PROCEDURES

Cell Culture

HeLa cell lines were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin, and 2 mM L-glutamine. hTERT-RPE1 Plk1^{as} cells were maintained in DMEM:F12 with 10% FBS, penicillin/streptomycin, and 2 mM L-glutamine. For time-lapse imaging, cells were maintained in CO₂-independent medium (Invitrogen) with 10% FBS.

Unless otherwise indicated, cells were incubated in 10 μ M Bl2536 (Thermo Fisher Scientific) for 2.5 hr, although severely defective CENP-A deposition was observed at concentrations down to at least 10 nM (Figure S2A). Where indicated, cells were incubated with 5 μ M flavopiridol (Sigma), 2 μ M AZ3146 (Tocris), 10 μ M 3MB-PP1 (Merck), or 10 μ M S-trityl-L-cysteine (STLC) (Sigma) for 1–2.5 hr. HeLa cells were synchronized by double thymidine block using 2 mM thymidine (Sigma) for all immunofluorescence and live-cell imaging experiments unless otherwise stated.

Cell Line Generation and Transfection

The cell lines used in this study are described in Table S1. Clonal cell lines stably expressing GFP^{LAP} or mCherry^{LAP} fusions were generated in HeLa cells as described previously (Cheeseman et al., 2004). Tetracycline-inducible cell lines were generated using the Flp-In T-Rex Expression system (Invitrogen) in a HeLa cell line (a gift from Stephen Taylor) and induced using 1 μ g/ml tetracycline (Sigma) approximately every 12 hr. Due to heterogeneity within

inducible cell lines, cells were matched for expression levels based on similar fluorescence where appropriate and cells that lacked detectable fluorescence were disregarded. The wild-type M18BP1 cDNA (Silva et al., 2012) was a gift from Lars Jansen (Gulbenkian Institute for Science). *E.-coli*-optimized and RNAi-resistant M18BP1, Mis18 α , Mis18 β , CENP-C, and corresponding phosphomutants were synthesized by Genewiz or generated using Quikchange (Agilent). Point mutants are described in Table S2.

The Plk1 locus was tagged with eYFP at the C terminus using CRISPR/Casmediated genome engineering in HeLa cells. The oligonucleotide sequences introduced for the targeting site and to amplify the 5' and 3' homology arms are listed in Table S3. Cas9 and single-guide RNA were expressed in pX330-BFP (Cong et al., 2013; a gift from Chikdu Shivalila and Rudolf Jaenisch, White head Institute/MIT) as described (Wang et al., 2013). The YFP donor plasmid derived from pL452 (Liu et al., 2003) was a gift from Paul Fields and Laurie Boyer (MIT). pX330 and the donor were cotransfected into HeLa cells at 2.5 μ g each and selected after 48 hr with 800 μ g/ml G418 (Life Technologies) for 2 weeks.

Small interfering RNAs (siRNAs) (Table S4) and a nontargeting control were obtained from Dharmacon. RNAi experiments were conducted using Lipofectamine RNAi MAX and serum-free OptiMEM (Invitrogen). DMEM plus 10% FBS was added after 5 or 6 hr. Cells were assayed 48 hr after transfection. Transient transfections were performed using Lipofectamine 2000 and OptiMEM (Invitrogen) according to manufacturer's instructions. The Premo FUCCI Cell Cycle Sensor BacMam 2.0 (Invitrogen) was used according to manufacturer's instructions.

Immunofluorescence and Microscopy

Immunofluorescence was conducted using the antibodies listed in Table S5. The pT702 phosphospecific antibody was generated against a synthesized phosphopeptide with the following amino acid sequence: GTLEN(pT) FEGHKSC (New England Peptide; Covance). Serum from the immunized rabbit was depleted against the unphosphorylated peptide and affinity purified against the phosphorylated peptide. For immunofluorescence using the phospho-specific antibody, cells were pre-extracted for 8–10 min in PBS plus 0.5% Triton X-100 before fixation in 4% formaldehyde in PBS. Cy2-, Cy3-, and Cy5-conjugated secondary antibodies were obtained from Jackson Laboratories. DNA was visualized using 10 μ g/ml Hoechst. G1 cells were identified by nuclear morphology (decondensed chromosomes) and microtubule staining: either two daughter cells connected by a midbody or two daughter cells connected by a microtubule pattern that is characteristic of cytokinesis failure due to Plk1 inhibition (e.g., Figure 2A).

Immunofluorescence images were acquired on a DeltaVision Core deconvolution microscope (Applied Precision) equipped with a CoolSnap HQ2 charge-coupled device (CCD) camera and deconvolved where appropriate. For immunofluorescence, approximately ten Z sections were acquired at 0.2 μ m steps using a 100×/ 1.4 numerical aperture (NA) Olympus U-PlanApo objective. In general, live-cell imaging was performed on the DeltaVision microscope using a 60×/1.42 NA Olympus U-PlanApo objective. For the initial characterization of localization (Figure 1A) and localization of M18BP1 following CDK inhibition (Figures 3E and 3F), images were acquired on a Nikon Ti-E inverted microscope with Perfect Focus system as part of an Andor Revolution 500 XD laser system including a Yokogawa CSU-X1 spinning disk confocal and Andor iXon 897 EMCCD camera using a 100×/1.49 NA Apo total internal reflection fluorescence (TIRF) objective. For live-cell imaging, approximately four Z sections were acquired at 1 μ m steps at 5–10 min

Scale bars, 5 µm. See also Figure S5.

⁽D) Left: schematic of M18BP1 showing residues phosphorylated by Plk1 in vitro. Right: schematic of an *N*-Terminal domain of M18BP1 (M18BP1-NT) that is sufficient for M18BP1 centromere localization, Mis18α recruitment and CENP-A deposition. SANTA, SANT-associated domain; Myb, Myb DNA-binding domain. (E) Immunofluorescence images showing new CENP-A-SNAP deposition in cells expressing GFP fusions of either M18BP1^{WT}-NT or M18BP1^{Plk1-A}-NT following treatment with the described siRNAs. New CENP-A-SNAP is labeled using SNAP-Cell TMR-Star.

⁽F) Quantification of centromeric fluorescence intensity of new CENP-A-SNAP following replacement of endogenous M18BP1 with RNAi-resistant GFP-M18BP1^{WT}-NT or GFP-M18BP1^{Pik1-A}-NT. Numbers are presented as a percentage of the intensity in M18BP1^{WT}-NT cells + control RNAi. The error bars represent SEM; n = 20 G1 cell pairs. ***p < 0.001 (Student's t test).

⁽G) Quantification of centromeric GFP-M18BP1^{WT}-NT or GFP-M18BP1^{Plk1-A}-NT fluorescence intensity in cells in which M18BP1 has been depleted. Localization of GFP-M18BP1^{Plk1-A}-NT fluorescence intensity in cells in which M18BP1 has been depleted. Localization of GFP-M18BP1^{Plk1-A}-NT fluorescence intensity in cells in which M18BP1 has been depleted. Localization of GFP-M18BP1^{Plk1-A}-NT fluorescence intensity in cells in which M18BP1 has been depleted. Localization of GFP-M18BP1^{Plk1-A}-NT fluorescence intensity in cells in which M18BP1 has been depleted. Localization of GFP-M18BP1^{Plk1-A}-NT is weak, even in the presence of the endogenous protein (Figure S5G). The error bars represent SEM; n = 20 G1 cell pairs. **p < 0.005 (Student's t test).





Figure 7. Model for the Control of CENP-A Deposition by Plk1 and CDK

CENP-A deposition is accomplished by a two-step regulatory mechanism integrating critical signals from Plk1 and CDK. During S, G2, and M phases, CDK inhibits Mis18 complex assembly. In G1, Plk1 at centromeres binds to and phosphorylates the Mis18 complex to promote its localization and license CENP-A deposition.

intervals for 1 hr, with refocusing using differential interference contrast before each time point. Images are scaled equivalently when shown for comparison, unless otherwise stated. Quantification of fluorescence intensity was conducted on unprocessed images using Metamorph (Molecular Devices).

CENP-A-SNAP Labeling

SNAP quench-pulse labeling was performed as described (Jansen et al., 2007) using a quench of 10 μ M SNAP-Cell Block and a pulse of either 3 μ M SNAP-Cell TMR-Star or 5 μ m SNAP-Cell Oregon Green (New England Biosciences). To assay CENP-A deposition in G1, cells were arrested in G1/S by double thymidine block and existing CENP-A-SNAP was saturated with nonfluorescent SNAP-Cell Block. Cells were released from the block for approximately 9 hr before addition of the fluorescent SNAP substrate. SNAP-Cell Oregon Green and SNAP-Cell TMR-Star were used as indicated in the figure legends. For RNAi experiments, cells were collected by mitotic shake off, split into two pools, and plated on polylysine-coated coverslips. Bl2536 was immediately added to one pool, and an equivalent volume of DMSO was added to the other. The cells were allowed to progress through G1 for 2–2.5 hr before fixation and immunofluorescence.

To assay CENP-A deposition in S phase, cells were quenched and released from G1/S as above, allowed to progress for 5 hr before addition of the fluorescent SNAP substrate, and fixed at 6 hr after release. S phase cells were then selected by punctate PCNA foci. To assay CENP-A deposition in G2 and M phase, cells were allowed to progress for 8 hr before addition of the fluorescent SNAP substrate. Cells were fixed at 9 hr (G2) or 10 hr (M) after release. G2 cells were identified by high cytoplasmic cyclin B. Mitotic cells were identified by DNA morphology or the presence of a mitotic spindle.

Protein Expression and Purification

GFP^{LAP}-Mis18α was isolated from HeLa cells as described previously (Cheeseman and Desai, 2005). To obtain cells in G1, cells were arrested over-

night in 20 nM nocodazole, collected by mitotic shake off, released by washout, and harvested when centromeric localization of Mis18 α was observed for the majority of cells by microscopy. The asynchronous sample was comprised of the cells that failed to arrest in nocodazole. The immunoprecipitated proteins were identified by mass spectrometry of tryptic digests using an LTQ XL Ion Trap mass spectrometer (Thermo Fisher Scientific) coupled with a reverse phase gradient over C18 resin (Phenomenex). Data were analyzed using SEQUEST software.

For recombinant expression of the Mis18 complex, *E.-coli*-optimized 6x-His-Mis18 α , *E.-coli*-optimized Mis18 β , and human M18BP1 were cloned into pST39 and expressed in Rosetta 2 (DE3)pLysS competent cells (EMD Biosciences). The complex was bound to nickel NTA-agarose (QIAGEN) in 50 mM sodium phosphate buffer (pH 8.0), 300 mM NaCl, 10 mM imidazole, and 0.1% Tween-20 and washed in 50 mM sodium phosphate buffer (pH 8.0), 500 mM NaCl, 40 mM imidazole, and 0.1% Tween-20. The complex was eluted in 50 mM sodium phosphate buffer (pH 7.0), 500 mM NaCl, and 250 mM imidazole and exchanged into 20 mM HEPES (pH 7.5), 150 mM KCl, and 1 mM dithiothreitol (DTT). The complex was analyzed by mass spectrometry to confirm the presence of all three components. 6x-His-GST-PBD (residues 326–603) and the 6x-His-MBP-Plk1 T210D plasmid were gifts from Daniel Lim and Michael Yaffe (MIT).

In Vitro Phosphorylation and Far-Western Analysis

Kinase assays were performed in 50 mM HEPES (pH 7.5), 150 mM KCl, 10 mM MgCl₂, 200 μ M ATP, and 1 mM DTT at 33°C for 45 min. For radioactive assays, 2 μ Ci γ ³²P-ATP was added to each reaction. 6x-His-MBP-Plk1-T210D purified from *E. coli* using Ni-NTA agarose (QIAGEN) was used for radioactive assays; His-Plk1 (Invitrogen; generated by baculovirus expression) was used for phosphosite mapping and far-western analysis. Phosphorylation by both of these kinases was abrogated by the addition of BI2536 (data not shown). Far-western analysis was performed as described using 6x-His-GST-PBD (Lowery et al., 2007).

Figure 6. Bypassing CDK and Plk1 Regulation Induces Cell-Cycle-Uncoupled CENP-A Deposition

(A) Immunofluorescence images showing GFP-Mis18 α localization in cells transiently transfected with either mCherry-CENP-C-M18BP1^{WT} or mCherry-CENP-C-M18BP1^{CDK-A}. Numbers represent centromeric fluorescence intensity as percent of cells transfected with CENP-C-M18BP1^{CDK-A} ± SEM; n = 20 cells; p < 0.001 (Student's t test).

(B) Schematic of the cell synchronization and CENP-A-SNAP labeling strategy to detect the deposition of newly synthesized CENP-A in S, G2, and M phases. (C) Immunofluorescence images showing the presence or absence of new CENP-A-SNAP (labeled with SNAP-Cell Oregon Green) at mitotic centromeres in cells expressing either mCherry-CENP-C-M18BP1^{CDK-A} or mCherry-CENP-C-Mis18 α after 24 hr of induction of the fusion. Centromeres are marked with α -CENP-A. (D) Quantification of the percent of cells observed with new CENP-A-SNAP in each cell cycle stage, 24 hr after induction of the fusion. $n \ge 100$ cells per stage. (E) Immunofluorescence images showing the recruitment of HJURP to centromeres throughout the cell cycle, indicative of ongoing CENP-A deposition. Centromeres are marked with anti-centromere antibodies. Numbers represent percentage of transfected cells in which GFP-HJURP was observed at centromeres; n = 50 cells.

(F) Immunofluorescence images showing deposition of new CENP-A-SNAP (labeled with SNAP-Cell Oregon Green) in S phase following treatment of CENP-C-Mis18α-expressing cells with BI2536. S phase cells are identified by punctate PCNA foci (data not shown). Numbers represent percent of cells showing robust centromeric new CENP-A-SNAP; n = 100 cells per condition.

(G) Immunofluorescence images summarizing mitotic defects observed in CENP-C-Mis18α-expressing cells after 48 hr of induction of the fusion. Centromeres are marked with anti-centromere antibodies.

(H) Quantification of the percent of cells observed with the chromosome alignment phenotypes depicted in (G). n = 100 cells. Scale bars, 5 μ m. See also Figure S6.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2014.06.016.

ACKNOWLEDGMENTS

We thank members of the I.M.C. laboratory, Defne Yarar, David Sabatini, Peter Reddien, Steve Bell, Frank Solomon, Terry Orr-Weaver, and Rick Young for discussions and critical reading of the manuscript. We are grateful to Daniel Lim and Michael Yaffe (MIT) for providing the GST-Plk1-PBD and advice on working with Plk1. We thank Aaron Straight (Stanford University) for the CENP-A-SNAP cell line, Prasad Jallepalli (Sloan Kettering) for the Rpe1-Plk1⁴⁸⁵ cell line, and Lars Jansen (Gulbenkian Institute) for the M18BP1 cDNA and CENP-A-SNAP plasmids. We thank Paul Fields and Laurie Boyer (MIT) and Chikdu Shivalila and Rudolf Jaenisch (Whitehead Institute and MIT) for advice and reagents for CRISPR/Cas9-mediated genome editing. This work was supported by a Scholar Award from the Leukemia & Lymphoma Society, a grant from the NIH/National Institute of General Medical Sciences (GM088313), and a Research Scholar Grant (121776) from the American Cancer Society to I.M.C. I.M.C. is a Thomas D. and Virginia W. Cabot Career Development Professor of Biology.

Received: December 12, 2013 Revised: March 28, 2014 Accepted: June 2, 2014 Published: July 17, 2014

REFERENCES

Archambault, V., and Glover, D.M. (2009). Polo-like kinases: conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. *10*, 265–275.

Arnaud, L., Pines, J., and Nigg, E.A. (1998). GFP tagging reveals human Pololike kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma *107*, 424–429.

Barnhart, M.C., Kuich, P.H.J.L., Stellfox, M.E., Ward, J.A., Bassett, E.A., Black, B.E., and Foltz, D.R. (2011). HJURP is a CENP-A chromatin assembly factor sufficient to form a functional de novo kinetochore. J. Cell Biol. *194*, 229–243.

Barr, F.A., Silljé, H.H.W., and Nigg, E.A. (2004). Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5, 429–440.

Bell, S.P., and Dutta, A. (2002). DNA replication in eukaryotic cells. Annu. Rev. Biochem. *71*, 333–374.

Black, B.E., Jansen, L.E.T., Foltz, D.R., and Cleveland, D.W. (2010). Centromere identity, function, and epigenetic propagation across cell divisions. Cold Spring Harb. Symp. Quant. Biol. 75, 403–418.

Burkard, M.E., Randall, C.L., Larochelle, S., Zhang, C., Shokat, K.M., Fisher, R.P., and Jallepalli, P.V. (2007). Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc. Natl. Acad. Sci. USA *104*, 4383–4388.

Cheeseman, I.M., and Desai, A. (2005). A combined approach for the localization and tandem affinity purification of protein complexes from metazoans. Sci. STKE 2005, pl1.

Cheeseman, I.M., Niessen, S., Anderson, S., Hyndman, F., Yates, J.R., 3rd, Oegema, K., and Desai, A. (2004). A conserved protein network controls assembly of the outer kinetochore and its ability to sustain tension. Genes Dev. *18*, 2255–2268.

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science *339*, 819–823.

Dambacher, S., Deng, W., Hahn, M., Sadic, D., Fröhlich, J., Nuber, A., Hoischen, C., Diekmann, S., Leonhardt, H., and Schotta, G. (2012). CENP-C facilitates the recruitment of M18BP1 to centromeric chromatin. Nucleus *3*, 101–110.

Dephoure, N., Zhou, C., Villén, J., Beausoleil, S.A., Bakalarski, C.E., Elledge, S.J., and Gygi, S.P. (2008). A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. USA *105*, 10762–10767.

Dunleavy, E.M., Roche, D., Tagami, H., Lacoste, N., Ray-Gallet, D., Nakamura, Y., Daigo, Y., Nakatani, Y., and Almouzni-Pettinotti, G. (2009). HJURP is a cellcycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell *137*, 485–497.

Elia, A.E.H., Cantley, L.C., and Yaffe, M.B. (2003a). Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299, 1228–1231.

Elia, A.E.H., Rellos, P., Haire, L.F., Chao, J.W., Ivins, F.J., Hoepker, K., Mohammad, D., Cantley, L.C., Smerdon, S.J., and Yaffe, M.B. (2003b). The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell *115*, 83–95.

Fachinetti, D., Folco, H.D., Nechemia-Arbely, Y., Valente, L.P., Nguyen, K., Wong, A.J., Zhu, Q., Holland, A.J., Desai, A., Jansen, L.E.T., and Cleveland, D.W. (2013). A two-step mechanism for epigenetic specification of centromere identity and function. Nat. Cell Biol. *15*, 1056–1066.

Foltz, D.R., Jansen, L.E.T., Bailey, A.O., Yates, J.R., 3rd, Bassett, E.A., Wood, S., Black, B.E., and Cleveland, D.W. (2009). Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell *137*, 472–484.

Fujita, Y., Hayashi, T., Kiyomitsu, T., Toyoda, Y., Kokubu, A., Obuse, C., and Yanagida, M. (2007). Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev. Cell *12*, 17–30.

Gascoigne, K.E., and Cheeseman, I.M. (2013). Induced dicentric chromosome formation promotes genomic rearrangements and tumorigenesis. Chromosome Res. 21, 407–418.

Gisselsson, D., Pettersson, L., Höglund, M., Heidenblad, M., Gorunova, L., Wiegant, J., Mertens, F., Dal Cin, P., Mitelman, F., and Mandahl, N. (2000). Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc. Natl. Acad. Sci. USA 97, 5357–5362.

Gómez-Rodríguez, M., and Jansen, L.E.T. (2013). Basic properties of epigenetic systems: lessons from the centromere. Curr. Opin. Genet. Dev. 23, 219–227.

Hayashi, T., Fujita, Y., Iwasaki, O., Adachi, Y., Takahashi, K., and Yanagida, M. (2004). Mis16 and Mis18 are required for CENP-A loading and histone deace-tylation at centromeres. Cell *118*, 715–729.

Jansen, L.E.T., Black, B.E., Foltz, D.R., and Cleveland, D.W. (2007). Propagation of centromeric chromatin requires exit from mitosis. J. Cell Biol. *176*, 795–805.

Kishi, K., van Vugt, M.A.T.M., Okamoto, K.-I., Hayashi, Y., and Yaffe, M.B. (2009). Functional dynamics of Polo-like kinase 1 at the centrosome. Mol. Cell Biol. *29*, 3134–3150.

Lagana, A., Dorn, J.F., De Rop, V., Ladouceur, A.-M., Maddox, A.S., and Maddox, P.S. (2010). A small GTPase molecular switch regulates epigenetic centromere maintenance by stabilizing newly incorporated CENP-A. Nat. Cell Biol. *12*, 1186–1193.

Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M., Rettig, W.J., Kraut, N., and Peters, J.-M. (2007). The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol. *17*, 304–315.

Liu, P., Jenkins, N.A., and Copeland, N.G. (2003). A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. *13*, 476–484.

Lowery, D.M., Clauser, K.R., Hjerrild, M., Lim, D., Alexander, J., Kishi, K., Ong, S.-E., Gammeltoft, S., Carr, S.A., and Yaffe, M.B. (2007). Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J. *26*, 2262–2273.

Maddox, P.S., Hyndman, F., Monen, J., Oegema, K., and Desai, A. (2007). Functional genomics identifies a Myb domain-containing protein family required for assembly of CENP-A chromatin. J. Cell Biol. *176*, 757–763.

Moree, B., Meyer, C.B., Fuller, C.J., and Straight, A.F. (2011). CENP-C recruits M18BP1 to centromeres to promote CENP-A chromatin assembly. J. Cell Biol. *194*, 855–871.

Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E.A., Sillje, H., and Barr, F.A. (2007). Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat. Cell Biol. *9*, 436–444.

Nigg, E.A. (2007). Centrosome duplication: of rules and licenses. Trends Cell Biol. *17*, 215–221.

Petronczki, M., Glotzer, M., Kraut, N., and Peters, J.-M. (2007). Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev. Cell *12*, 713–725.

Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., et al. (2008). Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell *132*, 487–498.

Shiromizu, T., Adachi, J., Watanabe, S., Murakami, T., Kuga, T., Muraoka, S., and Tomonaga, T. (2013). Identification of missing proteins in the neXtProt

database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J. Proteome Res. *12*, 2414–2421.

Silva, M.C., Bodor, D.L., Stellfox, M.E., Martins, N.M., Hochegger, H., Foltz, D.R., and Jansen, L.E. (2012). Cdk activity couples epigenetic centromere inheritance to cell cycle progression. Dev. Cell *22*, 52–63.

Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krssák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. *17*, 316–322.

Wang, H., Yang, H., Shivalila, C.S., Dawlaty, M.M., Cheng, A.W., Zhang, F., and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell *153*, 910–918.

Wolfe, B.A., Takaki, T., Petronczki, M., and Glotzer, M. (2009). Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol. 7, e1000110.